We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVersarien Regulatory News (VRS)

Share Price Information for Versarien (VRS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.1075
Bid: 0.105
Ask: 0.11
Change: 0.00125 (1.18%)
Spread: 0.005 (4.762%)
Open: 0.10625
High: 0.00
Low: 0.00
Prev. Close: 0.10625
VRS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Placing to raise £400,000

19 Jan 2024 07:00

RNS Number : 2199A
Versarien PLC
19 January 2024
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS AMENDED) AS IT FORMS PART OF THE DOMESTIC LAW OF THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 (AS AMENDED). UPON PUBLICATION OF THIS ANNOUNCMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

19 January 2024

 

Versarien plc

 

("Versarien" or the "Company")

 

Placing to raise £400,000

 

Versarien plc (AIM: VRS), the advanced materials engineering group, announces it has raised £400,000 (before expenses) by way of a placing (the "Placing") of 500,000,000 new ordinary shares in the capital of the Company ("Placing Shares") at a price of 0.08 pence per share (the "Placing Price").

 

Highlights

 

· Versarien has raised £400,000, before expenses, through the placing of 500,000,000 new ordinary shares in the capital of the Company at a price of 0.08 pence per share

· The net proceeds of the Placing will be used for corporate and working capital purposes as the Company seeks to capitalise on the growing number of opportunities in its pipeline whilst continuing to progress its asset sales

· The issue of the Placing Shares is within existing authorities granted by shareholders at the general meeting of the Company held on 10 January 2024 and therefore no shareholder approval is required for the Placing

 

Use of Proceeds and Turnaround Strategy

 

The net proceeds of the Placing will be used for corporate and working capital purposes as the Company seeks to capitalise on the growing number of opportunities in its pipeline. Recent new projects include a sales agreement with Go To Gym to bring Graphene-WearTM products to Colombia, Brazil and the USA, and Versarien's subsidiary, Gnanomat, entering into an agreement to co-develop advanced materials with IRPC, a Thai petroleum and petrochemical company. These projects, along with a pipeline of other opportunities currently being pursued demonstrate the longer term prospects for the business.

 

As announced on 20 December 2023, the mature businesses and the intellectual property and plant acquired from Hanwha Aerospace in 2020 continue to be marketed for sale and the Company is progressing discussions with a number of interested parties, though the timing of any asset sales and the quantum of the funds that may be received remains uncertain.

 

Stephen Hodge, Chief Executive Officer of Versarien, commented:

 

"In the short time since the Company Update announced on 20 December, the commercial, licencing and grant opportunities have continued to grow. This further funding will help us to progress the conversion of these leads while the asset sale discussions continue. We look forward to updating the market in due course."

 

Admission and Total Voting Rights

 

Application has been made for admission of the Placing Shares to be admitted to trading on AIM ("Admission") on or around 24 January 2024. The Placing Shares will rank pari passu in all respects with the Company's existing ordinary shares. Following Admission, the total number of ordinary shares in the Company in issue will be 996,169,507. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure and Transparency Rules.

 

For further information please contact:

 

Versarien

Stephen Hodge, Chief Executive Officer

Chris Leigh, Chief Financial Officer

 

c/o IFC

SP Angel Corporate Finance (Nominated Adviser and Broker)

Matthew Johnson, Adam Cowl

+44 (0)20 3470 0470

 

 

IFC Advisory Limited (Financial PR and Investor Relations)

Tim Metcalfe, Zach Cohen

+44 (0) 20 3934 6630

 

About Versarien:

 

The strategy of Versarien plc (AIM:VRS) is to be a development led advanced materials company focussed on specific sectors that will lead to a light manufacturing and licensing model.

 

For further information please see: http://www.versarien.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOEGPUGWGUPCPGR
Date   Source Headline
28th Mar 20247:00 amRNSAudited Results for year ended 30 September 2023
28th Mar 20247:00 amRNSTotal Voting Rights
20th Mar 20248:33 amRNSPlacing to raise £615,000
14th Mar 20247:00 amRNSSouth American Graphinks Agreements
11th Mar 20247:00 amRNSSale of Korean Assets and Licencing of IP
16th Feb 20242:22 pmRNSNotification of final results
7th Feb 20247:00 amRNSReceipt of Legal Claims
31st Jan 20247:00 amRNSTotal Voting Rights
23rd Jan 20244:53 pmRNSHolding(s) in Company
23rd Jan 20241:24 pmRNSHolding(s) in Company
19th Jan 20247:00 amRNSPlacing to raise £400,000
10th Jan 202411:29 amRNSResult of General Meeting
20th Dec 20237:00 amRNSCompany Update and Notice of General Meeting
30th Nov 20237:00 amRNSTotal Voting Rights
8th Nov 20237:00 amRNSPlacing to raise £454,822
30th Oct 202311:52 amRNSResult of General Meeting
30th Oct 20237:00 amRNSGeneral Meeting Statement
12th Oct 20237:00 amRNSNotice of General Meeting
2nd Oct 20237:00 amRNSCorporate Update
13th Sep 20237:00 amRNSTurnaround Strategy - Gnanomat Grant Award
31st Jul 20237:00 amRNSTotal Voting Rights
18th Jul 20234:31 pmRNSDirectorate Changes
14th Jul 20237:00 amRNSPlacing to raise £650,000
4th Jul 202310:54 amRNSResult of General Meeting
4th Jul 20237:00 amRNSGeneral Meeting Statement
15th Jun 20237:00 amRNSNotice of General Meeting
9th Jun 20237:00 amRNSInterim Results
31st May 20237:00 amRNSTotal Voting Rights
17th May 20237:00 amRNSSuccessful Cementene precast concrete trials
3rd May 20239:30 amRNSPlacing and Update on Turnaround Strategy
31st Mar 20237:00 amRNSTotal Voting Rights
29th Mar 202311:22 amRNSResult of AGM
29th Mar 20237:00 amRNSAGM Statement
15th Mar 20237:00 amRNSPlacing to raise £318,000
14th Mar 20232:56 pmRNSFurther re Resignation of Chief Executive Officer
10th Mar 20237:00 amRNSResignation of Chief Executive Officer
6th Mar 20237:00 amRNSCostain Civil Engineering Project
1st Mar 202312:00 pmRNSUmbro Launch
28th Feb 20237:00 amRNSNotice of AGM and Posting of Annual Report
21st Feb 20237:00 amRNSResults for the 18 months ended 30 September 2022
9th Feb 20238:33 amRNSAIM Rule 17 Update
27th Jan 20237:00 amRNSGraphene-Wear OEKO-TEX Eco Passport certification
24th Jan 20231:56 pmRNSFinal Results Update
30th Dec 20227:00 amRNSTotal Voting Rights
6th Dec 20229:40 amRNSPlacing to raise £1.85 million
5th Dec 20224:40 pmRNSSecond Price Monitoring Extn
5th Dec 20224:35 pmRNSPrice Monitoring Extension
5th Dec 20227:00 amRNSG-SCALE Update & Innovate UK Loan Variation
2nd Dec 20224:35 pmRNSPrice Monitoring Extension
1st Dec 20224:41 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.